Teva announced today that it has made a definitive offer to buy ratiopharm for an EV of €3,625m (€600m of debt repayment and the remainder equity). This represents 2.2x 2009 sales and approximately 11.6x 2009 EBITDA, once the losses at ratiopharm’s biogenerics business are...
Cephalon buys Mepha, but why?
Cephalon announced today that will pay approximately CHF 622.5m ($590m) to acquire Mepha from the Merckle family. Mepha, which used to be part of ratiopharm (also currently the subject of a sale process), is a branded generic company that is the market leader in...